Nautilus

Why Joel Osteen, “The Smiling Preacher,” Is So Darn Appealing

Right out of the gate, Osteen is using three of Antonakis’ identified tactics: an animated voice, facial expressions, and gestures.Photograph by Cooper Neill / Getty

It’s hard to quantify charisma, but by any measure Joel Osteen has some pretty impressive stats. Every week, the man some call “The Smiling Preacher,” draws an estimated 43,500 individuals to his Lakewood Church, which he moved into a former professional basketball stadium just off Houston’s Highway 59 in 2005. Osteen’s weekly sermons are beamed across seven networks in the United States and, by some estimates, reach 95 percent of the nation’s households and more than 150 countries.

The 55-year-old pastor, with his boyish good looks, ubiquitous incisors, and his impeccably coiffed mane of wavy, brown locks, oversees a budget estimated at upward of $70 million. He has penned no less than seven best sellers (most

You're reading a preview, sign up to read more.

More from Nautilus

Nautilus7 min read
A Doctor Puts Telemedicine to the Test During COVID-19: An advocate of virtual exams has a second opinion.
It was the first day after the San Francisco Bay Area declared that residents shelter in place, and I was getting ready to see patients. I generally dress in a dry-cleaned shirt, slacks, and a tie. I’m a pediatrician and feel parents deserve to see a
Nautilus5 min readSociety
The Good and Bad News from a Coronavirus Pandemic Model: An alarming warning from experts before the real outbreak.
How many people could die from a novel coronavirus infection? Of course, no one knows. But just before anyone had a hint of COVID-19, we got an estimate from a panel of health, security, and economic experts: 65 million deaths worldwide within 18 mon
Nautilus4 min readSociety
Will We Have a COVID-19 Vaccine Before 2021?
Is there a vaccine for SARS-CoV-2? The internet is awash with articles and posts seeking to shed light on this very question. Currently, there is no approved vaccine against SARS-CoV-2. While several companies have announced vaccine candidates in dev